Background

Immunotherapy in the field of cancer therapy aims to trigger an immune response that is targeting tumor cells. Monoclonal antibodies against tumor-specific antigens have become part of many cancer treatments. Besides, several different formats of immunoreactive molecules have been engineered. E.g. chimeric antigen receptor (CAR) molecules that have an antibody-derived antigen recognition domain and a T-cell activation domain are designed to give T-cells the ability to target a specific antigen. Patient derived CAR T-cells are produced ex vivo as cellular anti-cancer immunotherapies and are reinfused into the patient as a new option of treatment.

NY-BR1 is identified as a potential target for antibody-based therapies of breast cancer and is considered as well-suited for specific CAR T-cells.